Fusen Pharmaceutical Company Limited (01652.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 9Sep 14Sep 18

Key dataSep 18, 2026

OpenHKD 0.74

From 52W high−47.80%

Volume50000.00

Market capHKD 613.99M

P/E (TTM)—

P/S (TTM)1.9x

Div yield—

Key dataSep 18, 2026

Open

HKD 0.74

From 52W high

−47.80%

Volume

50000.00

Market cap

HKD 613.99M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

20.8x

P/E (TTM)

—

RSI (14)

42.7

MomentumView details →

1D Return

−1.19%

YTD Return

+3.75%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

20.8x

EV/Sales

2.7x

P/S (TTM)

1.9x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

41.98%

Net Margin

−0.85%

EBITDA Margin

13.04%

ROE (TTM)

−0.68%

ROA (TTM)

−0.19%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

+14.64%

EPS YoY

+98.62%

FCF YoY

−42.43%

Revenue CAGR 3Y

−17.78%

EPS CAGR 3Y

+93.88%

EBITDA YoY

+300.51%

MomentumView details →

1D Return

−1.19%

YTD Return

+3.75%

1Y Return

−14.43%

RSI (14)

42.7

vs 50D SMA

−13.72%

vs 200D SMA

−15.68%

Capital & dividendView details →

Debt/Equity

0.91x

Current Ratio

0.55x

Quick Ratio

0.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

−65.57%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

517.26M

Net Income (TTM)

−177.32M

Op. CF (TTM)

—

Latest newsMore news →

Fusen Pharmaceutical announced that four of its products were provisionally selected in China's 12th national centralized drug procurement tender on July 31, 2026.48d ago

Fusen Pharmaceutical's subsidiary Henan Fusen Pharmaceutical received approval from the National Medical Products Administration to market its drug Doxazosin Mesylate Extended-Release Tablets (trademark: Yijianping) for the treatment of mild-to-moderate hypertension and benign prostatic hyperplasia.69d ago

Similar companies

Zhongzhi Pharmaceutical Holdings Limited03737.HK Aquestive Therapeutics, Inc.AQST Evotec SEEVO Tilray Brands, Inc.TLRY Collegium Pharmaceutical, Inc.COLL Lee's Pharmaceutical Holdings Limited00950.HK Find similar companies →

Latest newsMore news →

Fusen Pharmaceutical announced that four of its products were provisionally selected in China's 12th national centralized drug procurement tender on July 31, 2026.48d ago Fusen Pharmaceutical's subsidiary Henan Fusen Pharmaceutical received approval from the National Medical Products Administration to market its drug Doxazosin Mesylate Extended-Release Tablets (trademark: Yijianping) for the treatment of mild-to-moderate hypertension and benign prostatic hyperplasia.69d ago